Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials
Potential conflict of interest: Dr. Harrison advises and is on the speakers' bureau for Merck and Vertex. He consults for and advises CLDF.
The views expressed herein are those of the authors and do not reflect the official policy or position of the San Antonio Military Medical Center, the US Army Medical Department, the US Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the US Government.
See Articles on Pages 514 and 524
No abstract is available for this article.